Religare Securities, in its latest research report on Dishman Pharma, has recommended BUY ratings, citing improved margins and attractive valuations as the main rationale behind it.
According to the research report, the company's net sales have increased by 23% and Adjusted PAT by 17.7% Y-o-Y which are among the best in the industry. In valuation terms also, the stock is trading at PE multiple of 9X which is 4x less than industry levels.
Religare clients can read the complete research report in Research section.
NSE Nifty Stock Ticker
Wednesday, June 10, 2009
Religare Securities recommends BUY on Dishman Pharma - 27th May
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment